Fisher M - Search Results

1

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.

van Leth F, Conway B, Laplumé H, Martin D, Fisher M, Jelaska A, Wit FW, Lange JM; 2NN study group. van Leth F, et al. Among authors: fisher m. Antivir Ther. 2004 Oct;9(5):721-8. Antivir Ther. 2004. PMID: 15535409 Clinical Trial.

2

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S; Liverpool TDM Database; UK CHIC Study. Stöhr W, et al. Among authors: fisher m. Antivir Ther. 2008;13(5):675-85. Antivir Ther. 2008. PMID: 18771051

3

An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.

Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B. Moyle G, et al. Among authors: fisher m. Antivir Ther. 2006;11(1):73-8. Antivir Ther. 2006. PMID: 16518962 Clinical Trial.

4

Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.

Sabin CA, Wilkins E, Murphy M, Fisher M, de Ruiter A, Easterbrook PJ, Leen C, Vlahakis E, Cane PA, Li X, Pillay D; UK Expanded Access Amprenavir Programme. Sabin CA, et al. Among authors: fisher m. Antivir Ther. 2003 Aug;8(4):301-8. Antivir Ther. 2003. PMID: 14518699

5

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.

Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Mocroft A, et al. Among authors: fisher m. Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26. Antivir Ther. 2012. PMID: 23013779

6

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al. Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462. Antivir Ther. 2009. PMID: 20032536 Free PMC article.

7

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team. Yuan J, et al. AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df. AIDS. 2011. PMID: 21505298 Free PMC article.

8

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.

9

Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord. Zugna D, et al. Antivir Ther. 2012;17(6):1039-48. doi: 10.3851/IMP2312. Epub 2012 Aug 15. Antivir Ther. 2012. PMID: 22910338 Free article.

10

Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee. Barber TJ, et al. Among authors: fisher m. Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818. Antivir Ther. 2011. PMID: 21900712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,474 results

Search Page